Biomedical Engineering Reference
In-Depth Information
29. Widmer N et al (2008) Principles of therapeutic drug monitoring. Rev Med Suisse 4:1644-1648
30. Widmer N et al (2008) Therapeutic drug monitoring: the clinical practice. Rev Med Suisse
4:1649-1660
31. Decosterd LA et al (2010) Multiplex ultra-performance liquid chromatography-tandem mass
spectrometry method for simultaneous quantification in human plasma of fluconazole, itra-
conazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidula-
fungin, and caspofungin. Antimicrob Agents Chemother 54:5303-5315
32. Fayet A et al (2009) A LC-tandem MS assay for the simultaneous measurement of new anti-
retroviral agents: raltegravir, maraviroc, darunavir, and etravirine. J Chromatogr B Analyt
Technol Biomed Life Sci 877:1057-1069
33. Fayet Mello A et al (2011) Successful efavirenz dose reduction guided by therapeutic drug
monitoring. Antivir Ther 16:189-197
34. Gotta V et al (2010) Suivi thérapeutique de l'imatinib. Forum Med Suisse 10:403-406
35. Gervasini G et al (2010) Pharmacogenetic testing and therapeutic drug monitoring are com-
plementary tools for optimal individualization of drug therapy. Eur J Clin Pharmacol
66:755-774
36. McMahon G et al (2009) Therapeutic drug monitoring in oncology: does it have a future?
Bioanalysis 1:507-511
37. Lennard L (2001) Therapeutic drug monitoring of cytotoxic drugs. Br J Clin Pharmacol
52(Suppl 1):75S-87S
38. Kamath AV et al (2008) Preclinical pharmacokinetics and in vitro metabolism of dasatinib
(BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Cancer Chemother Pharmacol 61:365-376
39. Lathia C et al (2006) Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib
clinical pharmacokinetics. Cancer Chemother Pharmacol 57:685-692
40. O'Brien SG et al (2003) Effects of imatinib mesylate (STI571, glivec) on the pharmacokinet-
ics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukae-
mia. Br J Cancer 89:1855-1859
41. White DL et al (2006) OCT-1-mediated influx is a key determinant of the intracellular uptake
of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro
sensitivity to imatinib. Blood 108:697-704
42. Widmer N et al (2006) Population pharmacokinetics of imatinib and the role of alpha-acid
glycoprotein. Br J Clin Pharmacol 62:97-112
43. Haouala A et al. (2011) Prediction of free imatinib concentrations based on total plasma
levels in GIST patients. Br J Clin Pharmacol, in press
44. Hazarika M et al (2008) Tasigna for chronic and accelerated phase Philadelphia chromo-
some-positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin
Cancer Res 14:5325-5331
45. Koch KM et al (2009) Effects of food on the relative bioavailability of lapatinib in cancer
patients. J Clin Oncol 27:1191-1196
46. Dai G et al (2008) Importance of characterizing determinants of variability in exposure:
application to dasatinib in subjects with chronic myeloid leukemia. J Clin Pharmacol
48(11):1254-1269
47. Houk BE et al (2010) Relationship between exposure to sunitinib and efficacy and tolerability
endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-anal-
ysis. Cancer Chemother Pharmacol 66:357-371
48. Klumpen HJ et al (2011) Moving towards dose individualization of tyrosine kinase inhibi-
tors. Cancer Treat Rev 37(4):251-260
49. Moore M et al (2005) Phase I study to determine the safety and pharmacokinetics of the novel
Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in
patients with advanced, refractory solid tumors. Ann Oncol 16:1688-1694
50. Peng B et al (2004) Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial
with chronic myeloid leukemia patients. J Clin Oncol 22:935-942
